Capital Cell, reportedly Europe’s first equity crowdfunding platform specializing in life science, has been shortlisted for the Best International Growth Business award at the UK Business Angels Association Investment Awards 2017. Capital Cell has been trading in Spain for just over 2 years, successfully closing 14 life science crowdfunding campaigns, including the country’s largest life science crowdfunding campaign of over €1.2M, for Bionure, a potential therapeutic cure for MS.
“We are absolutely thrilled that Capital Cell has been recognised so early on in its expansion into the UK, ” shared UK Director Laura Ferguson. ‘The reception to our arrival has been overwhelmingly positive from players throughout the life science ecosystem, including specialised investors such as Angels in MedCity, with whom we are collaborating closely, as well as the NHS innovation, science parks and startup incubators. It’s wonderful to have that traction formally recognised.”
Scaling up from its Barcelona-based platform, Capital Cell UK launched earlier in June with a range of companies solving unmet needs from malaria control to female fertility enhancement and autoimmune disease.
“Capital Cell has already proven itself as a platform for early stage investment in a very challenging environment, so we are extremely excited about scaling up in the UK, which is a global leader not only in life science innovation but also in equity crowdfunding,” added Capital Cell Chairman and lead investor Ian Tomlinson. “As an investment area, life science has the potential for both huge social impact and significant financial returns and the companies listed on Capital Cell are all trying to solve a major unmet medical need. By opening up these investment opportunities to more people we hope to be able to help the UK remain at the cutting edge of life science commercialisation.”